14.74
+0.58(+4.10%)
Currency In USD
| Previous Close | 14.16 |
| Open | 14.23 |
| Day High | 14.87 |
| Day Low | 14.16 |
| 52-Week High | 19.18 |
| 52-Week Low | 4.45 |
| Volume | 1.2M |
| Average Volume | 1.16M |
| Market Cap | 808.74M |
| PE | -3.78 |
| EPS | -3.9 |
| Moving Average 50 Days | 15.24 |
| Moving Average 200 Days | 14.05 |
| Change | 0.58 |
If you invested $1000 in uniQure N.V. (QURE) 10 years ago, it would be worth $441.19 as of September 18, 2025 at a share price of $14.74. Whereas If you bought $1000 worth of uniQure N.V. (QURE) shares 5 years ago, it would be worth $353.56 as of September 18, 2025 at a share price of $14.74.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
uniQure Announces Initial AMT-191 Phase I/IIa Data Showing Sustained Increases in α-Gal A Enzyme Activity in Patients with Fabry Disease
GlobeNewswire Inc.
Sep 05, 2025 11:05 AM GMT
~ All patients in the first cohort achieved between 27- to 208-fold increases in α-Gal A activity relative to mean normal level ~ ~ All patients in first cohort discontinued enzyme replacement therapy ~ ~ Preliminary data show AMT-191 has a manageabl
uniQure to Announce Second Quarter 2025 Financial Results
GlobeNewswire Inc.
Jul 22, 2025 11:05 AM GMT
uniQure to host earnings call on Tuesday, July 29, 2025 at 8:30 a.m. ETLEXINGTON, Mass. and AMSTERDAM, July 22, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients wit
uniQure Announces Appointment of Kylie O’Keefe as Chief Customer and Strategy Officer
GlobeNewswire Inc.
Jun 11, 2025 12:00 PM GMT
~ Proven biotech executive to lead commercialization of AMT-130 in Huntington’s disease ~ LEXINGTON, Mass. and AMSTERDAM, June 11, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapi